Market News

CWT's third-quarter earnings miss estimates amid higher taxes and costs, despite revenue growth and rate increases.

KRP gears up for Q3 2026 earnings, with higher oil prices and strong revenue growth estimates in focus.

WEX (WEX) is seeing improving mobility transaction volumes, but activity excluding its BP (BP) contr

Apple just posted record iPhone and Mac demand, authorized another $100 billion in buybacks, and sits at a valuation that punishes any misstep. Before...

Pinterest's (PINS) Q3 results and Q4 guidance point to growth deceleration after a stronger first ha

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Micron stock was dropping as Intel highlighted the cost of surging memory prices.

The grocery technology company has agreed to sell itself to DoorDash. Together, can they take a bigger swing at e-commerce giants like Amazon and Walm...

By Lisa Thompson NYSE: MHH READ THE FULL MHH RESEARCH REPORT Mastech Digital (NYSE: MHH) is in the midst of a transformation of itself and its industr...

Key TakeawaysBrightSpring Health Services stock jumped 12% as adjusted EBITDA rose 42% and 2026 guidance went up. Gross profit per script rose 27% in ...

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

2026-10-30. The following slide deck was published by BrightSpring Health Services, Inc.

CVS Health has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

FISV is set to post challenging Q3'26 earnings results, with revenues falling 1.6% and EPS down 15.7%, amid segment weakness, rising costs and margin ...

Some of the stock trades made by members of the House and Senate might surprise you.

Sleep device revenue grew 6% as AI tools boost therapy compliance and partnerships expand.

Positive operating cash flow and record revenue highlight a milestone quarter.

Core earnings fell 18% YoY; management reaffirmed full-year guidance.

Cabozantinib sales grew 11% year over year as zanzalintinib advances toward FDA decisions.